Prognostic Biomarkers for Chagas Disease

New research identifies metabolic signatures that could help predict which patients with Chagas disease are most likely to develop serious cardiac complications

November 3, 2026
2 min

The Pathologist

At a Glance

Category	Detail
Condition	Chronic Chagas disease and risk of cardiac progression
Key Mechanisms	Blood metabolites, including lipid-related molecules, were associated with subsequent cardiac deterioration; the proposed approach measures host metabolic changes rather than detecting the parasite.
Target Population	People with chronic Chagas disease, particularly those initially without cardiac involvement.
Care Setting	Research-stage prognostic assessment using stored serum samples; routine clinical use has not been established.

Key Highlights

The study analyzed stored serum from 72 patients with chronic Chagas disease in Bolivia using liquid chromatography–mass spectrometry.
Among patients initially free of cardiac involvement, 15 developed more advanced disease during follow-up and 48 remained stable.
Researchers identified eight individual metabolites associated with future progression.
Of 45 candidate biomarker panels, 10 achieved at least 60% sensitivity and 90% specificity.
The findings require validation in larger, geographically diverse studies before routine diagnostic use.

Guideline-Based Recommendations

Diagnosis

The article describes an investigational metabolite-based prognostic approach, not an established diagnostic test.

Management

The article does not provide treatment recommendations based on these biomarkers.

Monitoring & Follow-up

The authors state that validated biomarkers could help identify patients for closer cardiac monitoring; clinical utility has not yet been established.

Risks

Available antiparasitic medications can cause significant adverse effects, complicating treatment decisions.
The study was relatively small; standardized testing methods and validation across geographically diverse populations are needed.

Patient & Prescribing Data

The study included 72 patients with chronic Chagas disease in Bolivia; 15 initially free of cardiac involvement developed more advanced disease during follow-up, while 48 remained stable.

The article reports no biomarker-guided prescribing results. It notes that uncertainty about progression complicates treatment decisions because antiparasitic medications can cause significant adverse effects.

Clinical Best Practices

Do not treat the candidate metabolite panels as established routine diagnostic tests; the article states that further validation and demonstration of clinical utility are needed.
The authors identify larger, geographically diverse studies and standardized testing methods as necessary next steps.
The article describes potential use of validated biomarkers for risk stratification in surveillance and clinical trial design, not as current clinical recommendations.